Joshua Resnick - Jan 3, 2025 Form 4 Insider Report for Cidara Therapeutics, Inc. (CDTX)

Role: Director
Signature: /s/ Shane Ward, Attorney-in-Fact
Stock symbol: CDTX
Transactions as of: Jan 3, 2025
Transactions value $: $0
Form type: 4
Date filed: 1/7/2025, 06:38 PM
Previous filing: Jun 21, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CDTX	Stock Option (right to buy)	Award	$0	+22.2K		$0.00	22.2K	Jan 3, 2025	Common Stock	22.2K	$26.62	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/3rd of the total number of shares subject to the award shall vest on January 3, 2026 and the remaining 2/3rds of the shares will vest in equal monthly installments over the following two year period such that the option is fully vested on January 3, 2028.
F2	Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Content

1/3rd of the total number of shares subject to the award shall vest on January 3, 2026 and the remaining 2/3rds of the shares will vest in equal monthly installments over the following two year period such that the option is fully vested on January 3, 2028.

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.